Portal vein thrombosis after hematopoietic cell transplantation: Frequency, treatment and outcome

Bone Marrow Transplantation

Volumn 29, Issue 4, 2002, Pages 329-333

  Kikuchi, K ^a   Rudolph, R ^a   Murakami, C ^a   Kowdley, K ^a   McDonald, G B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombin III; Hematopoietic cell transplantation; Portal vein thrombosis; Protein C; Thrombolytic therapy; Veno occlusive disease

Indexed keywords

ACICLOVIR; ALKALINE PHOSPHATASE; ALTEPLASE; ANTICOAGULANT PROTEIN; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; HEPARIN; MELPHALAN; METHOTREXATE; PROTEIN C; THIOTEPA;

ADULT; AGED; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOPPLER FLOWMETRY; FEMALE; FIBRINOLYTIC THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERCOAGULABILITY; LEUKEMIA; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; MYELOMA; PORTAL VEIN BLOOD FLOW; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR; TREATMENT OUTCOME; VIRUS INFECTION; WEIGHT GAIN; WHOLE BODY RADIATION;

ADULT; AGED; ANTITHROMBIN III; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER CIRCULATION; MALE; MIDDLE AGED; PORTAL VEIN; PROTEIN C; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 85047697883     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703368     Document Type: Article

References (36)

1. Portal vein thrombosis: A review
2. Deficiency of protein C in patients with portal vein thrombosis
3. Portal vein thrombosis due to antithrombin III deficiency. A case report
4. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis
5. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma
6. Naturally occurring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of veno-occlusive disease of the liver
7. Multiple organ dysfunction syndrome in bone marrow transplantation
8. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules
9. Thrombotic complications of BMT: Association with protein C deficiency
10. Acute portal vein thrombosis after autologous stem cell transplantation
11. Sinus venous thrombosis
12. Treatment of superior vena cava syndrome with recombinant tissue plasminogen activator in a sickle cell patient undergoing bone marrow transplantation
13. Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation
14. Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma
15. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
16. Diagnosis of portal vein thrombosis: Value of color doppler imaging
17. Duplex assessment of the portal venous system
18. Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors
19. Venocclusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
20. Hepatobiliary complications of hematopoietic stem cell transplantation
21. Venocclusive disease of the liver after busulfan, melphalan, and thioTEPA conditioning therapy: Incidence, risk factors, and outcome
22. Venocclusive disease of the liver: Prospective study of US evaluation
23. Venocclusive liver disease after bone marrow transplantation: Findings at duplex sonography
24. Sonographic diagnosis and hemodynamic correlation in veno-occlusive disease of the liver
25. Diagnosis of venoocclusive disease of the liver after bone marrow transplantation: Value of duplex sonography
26. Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: Value of gray-scale and Doppler US in 100 patients
27. Venocclusive disease of the liver after marrow transplantation: Histologic correlates of clinical signs and symptoms
28. Decrease in hepatic nitric oxide production contributes to hepatic veno-occlusive disease (HVOD)
29. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation
30. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: A prospective study
31. Results of a phase I trial of antithrombin III as prophylaxis in bone marrow transplant patients at risk for veno-occlusive disease
32. No association between activated protein C (APC) resistance and hepatic veno-occlusive disease (VOD) following stem cell transplantation
33. The prothrombin gene variant G20210A but not factor V Leiden may be associated with veno-occlusive disease following BMT
34. Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients
35. Venocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation